Upgrade to SI Premium - Free Trial

Celldex (CLDX)

28.62 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP May 15, 2026 4:02 PM - SEC Filing Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Bellevue Group AG May 15, 2026 2:37 PM - SEC Filing Celldex Therapeutics (CLDX) PT Raised to $54 at Wells Fargo May 13, 2026 6:04 AM - StreetInsider Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP May 12, 2026 10:19 AM - SEC Filing Celldex Therapeutics (CLDX) PT Raised to $48 at Barclays May 8, 2026 4:05 AM - StreetInsider Celldex (CLDX) Tops Q1 EPS by 1c May 7, 2026 5:45 PM - StreetInsider Form 10-Q Celldex Therapeutics, For: Mar 31 May 7, 2026 4:09 PM - SEC Filing Form 8-K Celldex Therapeutics, For: May 07 May 7, 2026 4:02 PM - SEC Filing Celldex Reports First Quarter Financial Results and Provides Corporate Update May 7, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: FMR LLC May 6, 2026 11:07 AM - SEC Filing Form SCHEDULE 13G Celldex Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 29, 2026 5:36 PM - SEC Filing Form ARS Celldex Therapeutics, For: Dec 31 April 29, 2026 8:02 AM - SEC Filing Form DEF 14A Celldex Therapeutics, For: Jun 25 April 29, 2026 8:01 AM - SEC Filing Barclays Double Upgrades Celldex Therapeutics (CLDX) to Overweight April 20, 2026 3:59 AM - StreetInsider Celldex to Present at Upcoming Investor Conference April 13, 2026 4:01 PM - Globe NewsWire Celldex Therapeutics closes $345 million stock offering April 6, 2026 10:54 AM - StreetInsider Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 6, 2026 10:53 AM - Globe NewsWire Form 424B5 Celldex Therapeutics, April 2, 2026 5:15 PM - SEC Filing Form 8-K Celldex Therapeutics, For: Apr 01 April 2, 2026 8:08 AM - SEC Filing Celldex prices $300 million stock offering at $29 per share April 1, 2026 9:48 PM - StreetInsider Celldex Announces Pricing of $300 Million Public Offering of Common Stock April 1, 2026 9:48 PM - Globe NewsWire Form 424B5 Celldex Therapeutics, April 1, 2026 4:08 PM - SEC Filing Celldex launches public offering of common stock April 1, 2026 4:01 PM - StreetInsider Celldex Announces Proposed Public Offering of Common Stock April 1, 2026 4:01 PM - Globe NewsWire Celldex reports quality of life gains in urticaria studies March 27, 2026 10:30 AM - StreetInsider Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Pat March 27, 2026 10:30 AM - Globe NewsWire Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: VANGUARD GROUP INC March 26, 2026 5:17 PM - SEC Filing Wolfe Research Upgrades Celldex Therapeutics (CLDX) to Outperform March 23, 2026 5:40 AM - StreetInsider Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Point72 Asset Management, L.P. March 10, 2026 6:42 PM - SEC Filing Full Article List